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and Steen Joop Bonnema1Abstract
Background: Patients with chronic autoimmune thyroiditis have impaired health-related quality of life. The
thyroid gland has a high selenium concentration, and specific selenoprotein enzyme families are crucial to immune
function, and catalyze thyroid hormone metabolism and redox processes in thyroid cells. Previous randomized
controlled trials have found that selenium supplementation decreases thyroid-disease-specific antibody levels.
We hypothesize that selenium might be beneficial in the treatment of chronic autoimmune thyroiditis.
Methods/Design: The CATALYST trial is an investigator-initiated randomized, blinded, multicentre clinical trial of
selenium supplementation versus placebo in patients with chronic autoimmune thyroiditis. Inclusion criteria:
age ≥18 years; serum thyroid peroxidase antibody level ≥100 IU/ml within the previous 12 months; treatment with
levothyroxine and written informed consent. Exclusion criteria: previous diagnosis of toxic nodular goitre, Graves’
hyperthyroidism, postpartum thyroiditis, Graves’ orbitopathy; previous antithyroid drug treatment, radioiodine
therapy or thyroid surgery; immune-modulatory or other medication affecting thyroid function; pregnancy,
planned pregnancy or breastfeeding; allergy towards any intervention or placebo component; intake of selenium
supplementation >55 μg/day; inability to read or understand Danish or lack of informed consent. The trial will
include 2 × 236 participants. The experimental intervention and control groups will receive 200 μg selenium-enriched
yeast or matching placebo tablets daily for 12 months. The experimental supplement will be SelenoPrecise®. The
primary outcome is thyroid-related quality of life assessed by the Thyroid Patient-Reported Outcome (ThyPRO)
questionnaire. Secondary outcomes include serum thyroid peroxidase antibody concentration; serum
triiodothyronine/thyroxine ratio; levothyroxine dosage; adverse reactions and serious adverse reactions and events.
Discussion: In this pragmatic trial, participating patients follow their usual treatment at their usual hospitals. In order
to collect high-quality data on the clinical course and quality of life, and to minimize missing data, an elaborate trial
management system has been designed. 12 months intervention duration was selected in consideration of the
primary outcome, thyroid-related quality of life.
Trial registration: ClinicalTrials.gov ID: NCT02013479.
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Chronic autoimmune thyroiditis (AIT), also known as
chronic lymphocytic thyroiditis or Hashimoto’s thyroid-
itis, is a common autoimmune disease, which most often
leads to impaired function of the thyroid gland [1]. Its
aetiology is based on a complex and poorly understood
interaction between genetic susceptibility [2] and a
number of environmental triggers [3,4]. In Denmark, the
overall yearly incidence of overt hypothyroidism, that is,
decreased circulating thyroid hormone levels, has been
estimated at 47.2/100,000 [5]. AIT has been estimated to
account for around 85% of these patients and is 8 to 9
times more frequent in women than in men [5,6].
Thyroid hormone production declines slowly in patients
with AIT, with 5% per year progressing to overt hypo-
thyroidism [7]. Standard treatment of AIT is levothyrox-
ine (LT4), based on its long half-life of 8 days and stable
generation of triiodothyronine (T3) by deiodination in
peripheral tissues [8]. The goal of treatment is to restore
euthyroidism and resolve symptoms of hypothyroidism.
This is generally accomplished by adjusting the dosage
of LT4 to normalize serum thyrotropin (TSH) levels.
With rare exceptions, LT4 treatment is lifelong in pa-
tients with AIT [9]. According to a comprehensive re-
view from 2006, health-related quality of life (HRQL) is
impaired in most patients with benign thyroid disorders.
However, the authors emphasized limitations due to
lack of a validated and standardized questionnaire for
thyroid-related quality of life assessment [10]. Subse-
quently, we have developed such a thyroid-related
quality of life questionnaire, ThyPRO, to overcome the
shortcomings and lack of validation of earlier HRQL
questionnaires [11-14].
Large-scale community-based studies have demon-
strated impaired well-being in euthyroid patients on LT4
treatment for primary hypothyroidism, indicating that
restoration of euthyroidism is not the only predictor of
good quality of life in patients with AIT [15,16]. In fact,
hypothyroidism, even when adequately treated, is associ-
ated with increased morbidity and mortality [17-20]. In
a cross-sectional study, by investigators from our group,
responses to ThyPRO were analyzed in relation to
thyroid volume, thyroid function and thyroid autoanti-
bodies. Results suggested that thyroid peroxidase anti-
body (TPO-Ab) positivity per se might be associated
with symptomatic distress in patients with AIT [21].
Selenium is a nonmetal mineral, a trace element and
an essential micronutrient, incorporated into selenopro-
teins as the 21st amino-acid, selenocysteine. Selenopro-
teins have a wide range of effects in, for example, redox
homeostasis, immunity, reproduction and thyroid hor-
mone metabolism [22]. The recommended daily selen-
ium intake in Denmark is 50 μg and 40 μg for men
and women, respectively, and it is believed that 10% ofDanish adults would benefit from increasing their intake
[23]. In a recent Danish study, serum selenium concen-
tration was inversely associated with thyroid volume,
supporting a role for selenium in the thyroid gland,
which indeed has the highest selenium concentration
of all tissues [22,24]. A number of selenoproteins are
expressed in thyrocytes. The most important of these
are the iodothyronine deiodinases (DIO1, DIO2) that
catalyze the formation of T3 from T4, and the glutathi-
one peroxidases (GPx1, GPx3, GPx4) that catalyze the
removal of peroxides and protect the thyrocytes from
oxidative stress [25]. Two randomized clinical trials have
shown no effect of selenium supplementation on serum
TSH and thyroid hormone concentrations in healthy
adults, even in those with moderately deficient selenium
status [26,27]. Meanwhile, in the majority of 13 random-
ized clinical trials, selenium, in various formulations,
effectively decreased serum TPO-Ab concentrations in
AIT patients [28-40]. Some of the trials also reported
other beneficial effects, including improvements in qual-
ity of life, although with limited presentation of the data
supporting this claim. However, a recent systematic re-
view concluded that evidence to support or discard the
efficacy of selenium supplementation in AIT patients is
inadequate, and highlights the need of additional ran-
domized placebo-controlled trials to investigate direct
clinical outcomes, in order to aid clinical decision mak-
ing [41].
Only two randomized clinical trials have investigated
the effect of selenium supplementation in patients with
Graves’ disease, the other major autoimmune thyroid
disease. One trial concluded that patients with Graves’
hyperthyroidism who received selenium, in a formula-
tion with multiple antioxidants and in addition to anti-
thyroid drugs (ATDs), attained euthyroidism faster than
patients treated with only ATDs [42]. The other trial
evaluated the effect of 200 μg selenium selenite daily in
159 euthyroid patients with mild Graves’ orbitopathy,
and demonstrated improved disease-specific quality of
life and a reduced disease severity, as compared with
placebo [43]. We are conducting a trial entitled ‘Selenium
supplementation in patients with Graves’ hyperthyroidism
(GRASS)’ (ClinicalTrials.gov NCT01611896). The purpose
of the GRASS trial is to investigate whether selenium, in
addition to the standard treatment with ATDs, in patients
with Graves’ hyperthyroidism, will lead to a decrease in
antithyroid treatment failure, faster remission and im-
proved quality of life during the first year of treatment. En-
rolment of 492 patients into the GRASS study was
initiated in December 2012. Patients are randomized to
intervention with 200 μg/day of selenium-enriched yeast
versus placebo for 24 to 30 months. The CATALYST and
GRASS trials are closely connected in terms of study
design and will largely be performed by the same group of
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protocol are identical to the GRASS protocol [44].
We hypothesize that the addition of selenium to the
standard treatment with LT4 in patients with AIT may
lead to an improved quality of life and reduce auto-
immune disease activity.
Methods/design
Objectives
The primary objective is to investigate the effect of 12
months’ intervention with selenium supplementation
compared with placebo in patients with AIT, on thyroid-
related quality of life, as measured using the ThyPRO
questionnaire.
Secondary objectives are to investigate the effect of
selenium supplementation compared with placebo on:
LT4 dosage; serum T3/T4-ratio; serum TPO-Ab concen-
tration; plasma selenium concentration; and immuno-
logical and oxidative stress biomarkers. Monitoring
adverse and serious adverse events and reactions consti-
tute additional secondary objectives.
Design
The CATALYST trial is an investigator-initiated ran-
domized, blinded, multicentre clinical trial of selenium
supplementation versus placebo in patients with AIT.
The trial has a parallel-group design with 1:1 allocation
to the experimental intervention group and the control
intervention group (Figure 1). Participants will be re-
cruited from four clinical trial sites in Denmark (Odense
University Hospital, Rigshospitalet, Bispebjerg Hospital,
and the Hospital of Southwest Denmark). The trial also
includes a register-based follow-up during the trial and
during a period after completion of the intervention.
Trial participants
All patients with a diagnosis of AIT who are referred to,
or followed-up at, a participating clinical trial site will be
considered for participation in this trial. In addition,
clinical trial sites may invite participants based on local
trial site patient data or advertise in local media or via
patient organizations. Patients may enter the CATA-
LYST trial if they comply with the inclusion and exclu-
sion criteria.
Inclusion criteria
Age ≥18 years; diagnosis of AIT with serum TPO-Ab ≥
100 IU/ml measured within the last 12 months; LT4
treatment based on an initial serum TSH ≥ 4.0 mU/l;
and written informed consent.
Exclusion criteria
Previous diagnosis of toxic nodular goitre, Graves’ hyper-
thyroidism, postpartum thyroiditis or Graves’ orbitopathy;previous radioiodine therapy, ATD treatment or thyroid
surgery; morbidity, rendering the participant unable to
process patient-reported outcomes or receive intervention
during the trial; immunomodulatory medication; other
medication known to affect thyroid function; pregnancy,
breastfeeding or planned pregnancy within the next 18
months; allergy towards any component in the selenium
or the placebo tablets; intake of selenium supplementa-
tion >55 μg/day; inability to read or understand Danish; or
lack of informed consent.
Trial intervention
Selenium
In this trial, oral tablets of selenium-enriched yeast will
be used. The experimental intervention will be 200 μg
selenium per day, corresponding to two 100 μg tablets
SelenoPrecise® in a formulation registered as a dietary
supplement and produced by Pharma Nord ApS, Vejle,
Denmark.
Placebo
The control intervention will be two placebo tablets per
day as inactive spray-dried baker’s yeast, comprising
250 mg yeast placebo, 80 mg cellulose, 65 mg dicalcium
phosphate, and ≤5 mg other inactive ingredients. Tablets
will be identical to the experimental intervention as
regards size, appearance, taste, smell and solubility and
will be produced by Pharma Nord ApS, Vejle, Denmark.
The trial data management system (TDMS)
Since the design will involve limited interaction between
participants and trial personnel, a considerable part of
the data collection, trial conduct, trial surveillance and
timing, is handled by a trial data management system
TDMS. This system, named PROgmatic, is described in
detail in an independent publication [45]. It consists of a
patient-survey interface, a trial-personnel interface, a
system-integration interface and a program ‘motor’. The
system features include secure web-based data entry;
electronic case report forms (eCRFs); central participant
registration and randomization; automated emails link-
ing to electronic patient-reported outcomes; automated
reminders to participants; automated notifications to
trial personnel regarding booking of trial visits, safety
and compliance alerts and monitoring of trial progress.
It will be used for collecting outcome data, adverse events,
and other study-relevant information; for timing of trial
events, that is, time for patient-reported outcomes and
trial visits; for identification of need for action (for ex-
ample, contact to a participant); and for delivery of output
to personnel or participants (for example, email notifica-
tions). In this way, the eCRFs are created by integration of
patient-input, trial-personnel input and collection of elec-
tronic data regarding biochemical analyses (that is, blood-
Figure 1 Trial flow chart (adapted from the CONSORT statement 2010).
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automatically logged. The TDMS complies with the secur-
ity policies of the participating hospitals and the Act on
Processing of Personal Data, and is approved by the
Danish Data Protection Agency.
Randomization
Randomization will be performed centrally by a consult-
ant at the SAS Institute A/S (Copenhagen, Denmark).
The allocation sequences will be computer-generated
with varying block size, and will be kept unknown to the
investigators. Randomization will be stratified by clinical
trial site and LT4 treatment duration (<3 months or ≥3
months) and the allocation ratio of intervention and
control will be 1:1.
Informed consent procedure
Potential participants include all patients with suspected
AIT who receive LT4 and are identified at referral or
visits to the outpatient clinics or via advertising, as pre-
viously described. When AIT is confirmed (serum TPO-
Ab ≥ 100 IU/ml, measured within the last 12 months),
the patient is invited to an information visit. This visit
involves obtaining medical history and written informed
consent, blood and urine sampling, and information
about trial contact as well as randomization.
Concomitant medication or treatment
The trial interventions are given in addition to conven-
tional LT4 treatment. Treatment of the hypothyroidism
per se will take place at participating clinical trial sites,
with LT4 treatment at all clinical trial sites aiming for a
serum TSH level within reference ranges, as recom-
mended in local clinical guidelines. Patients are normally
followed with blood sampling every 1 to 3 months to ad-
just LT4 dosage according to TSH levels, as well as visits
in the outpatient clinic every 3 to 6 months. Participants
in the CATALYST trial will be followed with blood sam-
pling during the trial period, as stated in local clinical
guidelines. Participants are advised not to take selenium
supplementation in addition to the intervention. A dose
of selenium common in multivitamin tablets is, however,
allowed and participants are instructed and informed
about this upon trial entry, and in the written participant
information. The participants’ consumption of additional
selenium supplements will be monitored during the trial
at specific time points.
Monitoring participant adherence to intervention
During the trial, participants self-report their adherence
to the intervention at the trial visits (3 months and 12
months after randomization) by stating the number of
days a week they take their tablets. Participants will
also be instructed to bring remaining tablets and emptycontainers to the 12 month visit, where they will be
counted and registered by an investigator or trial nurse.
Discontinuation
A participant who no longer wishes to participate in the
trial can withdraw informed consent at any time without
need of further explanation, with no consequence on the
participant’s further treatment. To conduct intention-to-
treat analyses, with as little ‘missing data’ as possible, the
investigator may ask the participant which aspects of
the trial he or she wishes to withdraw from. This could
involve the trial intervention, participation in the remai-
ning follow-up assessments, or use of already collected
data in the data analyses. The investigators shall discon-
tinue a participant from the trial intervention at any
time, if the participant complies with any of the exclu-
sion criteria during the intervention period or experi-
ences intolerable adverse reactions. In both cases, the
investigator or the treating physician shall, if possible,
encourage the participant to continue with follow-up
assessment and allow the use of already collected data in
the analyses.
Blinding
Blinding will be maintained for all parties in the trial,
throughout all aspects of the trial. Statistical analyses
will be performed with the blinding intact, for example,
the experimental intervention and control intervention
group will be randomly coded as ‘A’ and ‘B’. Two conclu-
sions will be drawn; one assuming that ‘A’ is the experimen-
tal intervention group and ‘B’ is the control intervention
group, and one assuming the opposite. Only after this will
the blinding be broken.
Safety
The selected dosage and the exclusion criterion regard-
ing additional selenium supplementation intake ensure
that participants have a total selenium intake of less than
300 μg per day, as recommended in current European
guidelines on tolerable upper intake level [46]. It has
previously been concluded that SelenoPrecise® is ad-
equately characterized, of reproducible quality, and that
there is no evidence of toxicity even at intake levels far
above 300 μg per day [47]. In a randomized clinical trial
(UK PRECISE) with 501 volunteer participants from
general practice, mean plasma selenium increased from
88.1 μg/l to 188.1 μg/l following 6 months supplementa-
tion with 200 μg/day SelenoPrecise [48]. While no
serious adverse events occurred, 12 adverse events were
reported, primarily stomach or abdominal discomfort,
which were equally distributed between the selenium
and placebo groups [48]. The tablets used were identical
to the planned experimental intervention agent in
CATALYST, and CATALYST participants are expected
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regard to baseline selenium status.
The safety profile of the dietary supplement used in the
CATALYST trial is based on the summary of product
characteristics (SPC) for the drug formulation of Seleno-
Precise® from the Danish Medicines Agency. Common
adverse reactions (between 1/10 and 1/100) are com-
plaints from the gastrointestinal system, while uncommon
(between 1/100 and 1/1,000) and rare (between 1/1,000
and 1/10,000) adverse reactions are mainly of a dermato-
logical nature.
Outcomes
Data will be collected for outcome assessment at six spe-
cified times during the trial (Table 1).
Primary outcome
Improved thyroid-related quality of life during the 12
months intervention after randomization, as measured by
one composite score from the ThyPRO questionnaire [49].
Secondary outcomes
Secondary outcome assessment is specified in Table 1.
Forkhead Box P3 mRNA will be measured as an im-
munological biomarker, and urinary 8-oxo-2'-deoxygua-
nosine and 8-oxoguanine will be measured as oxidative
stress biomarkers.Table 1 Timing of data collection
Variable Inclusion
baseline
Follow-up 6
weeks ± 1 week
Fol
mo
w
Visit x
Weight xv
Medical treatment xv
ThyPRO xr xr
TSH, FT4, FT3 xs
TPO-Ab xs
LT4 dosage xv
Immunological and oxidative
stress biomarkers
xs
Selenium xs
Creatinine/iodine ratio
in spot urine
xs
Tablet count
Consumption of additional
selenium
xv
Adverse reactions
Serious adverse reactions and
events (SARs, SUSARs and SAEs)
All assessments must be made at the time points specified above. If not possible at
assessment shall be noted in the specified electronic case report form (eCRF). xv, an
data management system (TDMS); xr, analyzed via patient-reported outcomes, adm
trial visits; xp, analyzed via public national registries at the end of the trial.Assessment of adverse reactions and events
The latest version of the SPC shall at all times be used
for the assessment of adverse reactions (ARs), which will
be reported as a secondary trial outcome. Participants
are questioned about ARs according to Table 1. In
addition, participants are instructed to contact their trial
contact person if they experience symptoms suggestive
of ARs.
In the assessment and reporting of serious adverse re-
actions (SARs), serious unexpected serious adverse reac-
tion (SUSARs) and serious adverse events (SAEs), data
on hospital admissions and mortality will be obtained
through national registries at the end of the trial. Also,
participants are informed and instructed to contact their
trial contact person if they are admitted to a hospital for
selenium intoxication, experience a clinical picture indi-
cative of selenium intoxication, or experience a clinical
picture that is unexpected but suspected to be related to
selenium intoxication. When a possible serious event
(SAE, SAR or SUSAR) is identified, details will be sought
from the patient’s medical record and through direct
contact with the patient. Any SAE, SAR or SUSAR will
be reported as an outcome measure.
Research biobank
A central research biobank, of buffy coat, serum, plasma
and urine samples, will be established for analyses oflow-up 3
nths ± 2
eeks
Follow-up 6
months ± 2
weeks
Follow-up 12
months ± 2
weeks
Follow-up 18
months ± 2
weeks
x x x
xv xv xv
xv xv xv
xr xr xr xr
xs xs xs
xs xs xs,
xv xv xv
xs xs xs
xs xs xs
xv xv
xv xv xv
xv xv xv
xp
the specified time, the assessment shall still be conducted, and the time of
alyzed via data obtained in eCRFs at trial visits, administered through the trial
inistered through the TDMS; xs, analyzed in blood or urine samples obtained at
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and for future use. Future sample analyses include
genome-wide association studies (regarding predictors of
experimental intervention effect, or other predictors of
autoimmunity) as may be specified in forthcoming pro-
tocols. Participants are informed orally and in writing,
and will consent to the withdrawal and storing of bio-
logical material in the CATALYST trial. For this pur-
pose, tubes of blood and urine will be collected at each
of the four trial visits. Trained trial personnel will per-
form blood sampling; the risks involved with blood sam-
pling are no more than with standard blood sampling.
Monitoring
The trial will be monitored according to the International
Committee of Harmonisation guidelines for good clinical
research practice (ICH-GCP) by internal monitoring [50].
Statistical analyses
Primary outcome: sample size estimation
The primary outcome is thyroid-related quality of life
during 12 months’ intervention, as measured by a com-
posite score from the ThyPRO questionnaire. Sample
size estimation is based on this outcome.
The trial should be sufficiently powered to identify a
difference between the intervention and the control
group of four points on the 0 to 100 ThyPRO composite
scale, corresponding to a small to moderate effect. In
previously obtained data, the standard deviation of
ThyPRO-scores (sigma level) was 20 points [14]. With a
correlation between observations on the same partici-
pant of 0.50, and a power of 80% and a type I error
probability (two-sided α level) of 0.05, a sample size of
236 experimental participants and 236 control partici-
pants is required. The sample size estimate is based on a
design with five repeated measurements having a com-
pound symmetry covariance structure [51].
Secondary outcomes: power estimation
Power calculations are based on serum TPO-Ab concen-
trations and LT4 dosage. Standard deviations used for
power calculations were extracted from unpublished
data in a study population of approximately 200 AIT
patients from Copenhagen and Odense University Hos-
pitals receiving LT4 treatment [14].
Serum TPO-Ab concentration
While a previous study has linked TPO-Ab positivity in
hypothyroid patients to impaired HRQL [20], we have
not found conclusive evidence in the literature that
the level of serum TPO-Ab among participants in this
trial, that is, AIT patients with serum TPO-Ab concen-
tration ≥100 IU/ml, has clinical implications. The power
estimate is based on a design with three repeatedmeasurements having a compound symmetry covariance
structure, with a standard deviation (σ level) of 535
IU/ml (unpublished data) [14], a correlation between ob-
servations on the same participant of 0.50, and a type I
error probability (two-sided α level) of 0.05. Under these
circumstances, a difference in serum TPO-Ab levels of
138 IU/ml between the experimental and control group
can be identified with 80% power. We find the power of
the trial to assess effect on serum TPO-Ab concentra-
tions acceptable.
LT4 dosage
In this trial, a difference in LT4 dosage of 25 μg/day be-
tween the experimental and control group following
intervention should be detected, since 25 μg/day is a
minimal dosage adjustment readily made by clinicians,
when patients are treated with the most common LT4
formulation (Eltroxin) on the Danish market. The power
estimate is based on a design with five repeated mea-
surements having a compound symmetry covariance
structure, with a standard deviation (σ level) of 81 μg/
day (unpublished data) [14], a correlation between ob-
servations on the same participant of 0.50, and a type I
error probability (two-sided α level) of 0.05. Under these
circumstances, the probability (power) of finding a true
difference in LT4 dosage of 25 μg/day between the ex-
perimental and control group following intervention is
92%, which we find acceptable.
Expected participant recruitment
The patient uptake areas for the participating clinical trial
sites comprise a total of 910,000 persons (Rigshospitalet:
70,000; Odense University Hospital: 350,000; Bispebjerg
Hospital: 270,000; Hospital of Southwest Denmark
(Esbjerg): 220,000).
Previous studies report an incidence of 40 per 100,000
per year of spontaneous (presumed autoimmune) hypo-
thyroidism after the implementation of iodine fortifica-
tion in Denmark [5,6]. This corresponds to 364 patients
per year in the given uptake area. A considerable pro-
portion of hypothyroid patients are treated in the pri-
mary care sector, and will neither be referred to nor
followed at a participating clinical trial site. Assuming an
inclusion of 30% of the annual incident patients, we will
be able to include 109 participants per year or nine par-
ticipants per month. Half of the 472 participants will be
included from the incident (LT4 treatment <3 months)
group, and this is expected to take 24 to 26 months. In
addition to this, established patients (LT4 treatment ≥ 3
months) with autoimmune thyroiditis are eligible for
inclusion. The prevalence of diagnosed and treated
hypothyroidism was 1% in a previous iodine fortification
program (DanThyr) with a population of 4,073 men and
women. 83% of hypothyroid patients had serum-TPO-
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of 1% among adults in our patient uptake area will be
approximately 10,000 individuals. We expect to recruit 236
participants from the prevalent patient group within the 24
to 26 month recruitment period of the incident patients.
Data analyses
Analyses will be performed using SAS (SAS Institute
Inc. ©, Cary, NC, USA), version 9.3 or later. All analyses
will be intention-to-treat analyses performed blinded with
the two intervention groups concealed as, for example, ‘A’
and ‘B’. Significance tests will be at the 5% level and
two-sided. Table 2 shows, for each outcome, its priority,
when it will be measured, the mathematical type of
measure, and the analytical procedure to be used when
analyzing the outcome values. The analytical procedures
and handling of missing values are described next.
Analytical procedures
Depending on the specific analytical category of each
outcome measure, one or two of three types of regres-
sion analyses will be applied (Table 2).
Analytical categories
Type 1 includes a continuous outcome measure (y) mea-
sured 3 to 6 times at 6 weeks, 3, 6, 12 or 18 months after
randomization. It is viewed as a linear function of time
(t). The model is:
y = a + b*I + c*t + d*I*t
Depending on the mean value structure in the two
groups, this model may be enhanced to include a second-
or third-degree polynomial. I is the intervention indicator,
and a, b, c and d are the coefficients of the regressionTable 2 Outcome measures
Outcome (priority) Times of m
ThyPRO composite scale score (P) Time sequen
ThyPRO hypothyroid symptoms (S) Time sequen
ThyPRO goitre symptoms (S) Time sequen
LT4 dosage (S) Time sequen
Serum TPO-Ab (S) Time sequen
Serum FT3/FT4 Ratio (S) Time sequen
Plasma selenium (S) Time sequen
Biomarkers of immunology and oxidative stress (S) Time sequen
Adverse reactions (S) End of trial
Serious adverse events (S) End of trial
Outcomes with priorities, times of measurement and mathematical types of quantit
outcome measure. Analytical categories 1 to 3 are defined in the main text. a, inclu
6 months, 12 months and 18 months after randomization); b, includes three measu
after randomization).equation. A mixed model with repeated measures will be
used. An unstructured covariance matrix will be used. In
the case of lack of convergence, the following covariance
structures will be tried in the specified order: the spatial
power law and the compound symmetric.
Type 2 includes a single continuous outcome measure.
The general linear univariate model will be used. As a sen-
sitivity analysis, a nonparametric test (Mann Whitney) will
be conducted and the result discussed.
Type 3 includes a count of events within a specified
period of counting as outcome measure. The generalized
linear model will be used with the Poisson distribution,
link = log and log (period) as offset. As a sensitivity ana-
lysis a nonparametric test (Mann Whitney) is conducted
to compare the distributions of rates between the groups
and the result discussed.
Missing values
If the distributions of the primary outcome measure dif-
fer significantly between the two intervention groups,
multiple imputations (MI) will be used to replace miss-
ing data with substituted values using SAS version 9.3 or
later. In the MI analysis, the model variables and add-
itional variables significantly related to the variables with
missing values of these variables will be used. Ten im-
puted data sets will be produced.
Ethical considerations
As specified by the Danish Medicines Agency, the
CATALYST trial is not subject under the Danish Medi-
cines Act (law 1180 by 12/12/2005, §88, section 1). The
CATALYST trial obeys the rules and regulations set down
by The Biomedical Research Ethics Committees, Danish
Data Protection Agency, and the health authorities. The
CATALYST trial will be conducted in accordance with theeasurements Mathematical type of quantity
(analytical category)
ce of six measurementsa Numerical (1 + 2)
ce of six measurementsa Numerical (1 + 2)
ce of six measurementsa Numerical (1 + 2)
ce of four measurementsb Numerical (1 + 2)
ce of four measurementsb Numerical (1 + 2)
ce of four measurementsb Numerical (1 + 2)
ce of four measurementsb Numerical (1 + 2)
ce of four measurementsb Numerical (1 + 2)
Rate (3)
Rate (3)
y with analytical categories. P, primary outcome measure; S, secondary
des five measurements relative to the reference time (6 weeks, 3 months,
rements relative to the reference time (3 months, 12 months and 18 months
Table 3 Time schedule
Time Task
July 2012 to
March 2014
Preparation and approval of trial protocol (Regional
Scientific Ethical Committees for Southern Denmark
and Danish Data Protection Agency) and trial
registration (ClinicalTrials.gov)
April 2014 First patient, first visit
August 2016 Last patient, first visit
February 2018 Last patient, last visit
Spring 2018 Analysis of biological samples and data.
Preparation of manuscripts
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the Regional Scientific Ethical Committees for Southern
Denmark (project ID: S-20130123).
Discussion
The data available from previous trials warrant further
investigation, since a benefit from selenium supplemen-
tation is still unproven in patients with AIT. In previous
trials of intervention with selenium in patients with AIT,
effect on serum TPO-Ab concentration has been the
primary outcome. Intervention durations of 3, 6, 9, and
12 months using different selenium formulations have
shown positive effects on serum TPO-Ab concentra-
tions. This trial will be the largest yet, with 472 partici-
pants, and the first to measure changes in quality of life,
by ThyPRO, as the primary outcome. The sample size
estimate does not take dropouts or off-trial use of selen-
ium supplements into account. Plasma selenium concen-
trations will be measured to assess selenium intake
during the trial. Importantly, utilizing the ThyPRO ques-
tionnaire will enable us to determine how selenium sup-
plementation may affect specific aspects of thyroid-
related quality of life in AIT patients. In assessing quality
of life, the effect of levothyroxine alone will be taken
into account by adjusting for TSH levels. Choosing a
12-month intervention period allows for a time sequence
of five measurements. The 6-month postintervention
follow-up period was added to assess sustained effects.
This trial will also look into selenium’s mechanisms of
action in AIT, by measuring biomarkers of immuno-
logical activity, and will be the first to evaluate whether
selenium supplementation affects LT4 dosage. Dosage
reduction is of clinical interest and discontinuation of
LT4 would be of direct clinical relevance. An effect of
selenium supplementation on LT4 dosage is conceivable,
owing to upregulation of selenoproteins involved in thy-
roid hormone synthesis or thyrocyte protection.
Participants will be stratified for LT4 treatment dur-
ation of more or less than three months, corresponding
to newly diagnosed and established patients, respectively.
Participants in the newly diagnosed patient group will
respond to LT4 treatment per se, in terms of restoration
of euthyroidism, while the established patient group will
not experience major fluctuation in the thyroid hormone
levels during the study period. The stratification also al-
lows an investigation of whether the newly diagnosed
and established patient groups respond differently to sel-
enium supplementation. This investigation will, however,
be strictly exploratory, as it is likely to be underpowered.
It is of major importance to the CATALYST trial’s ini-
tiators that the results will be as directly applicable to
daily clinical practice as possible. Therefore, it will be
conducted as a pragmatic trial [52], with participating
patients following their usual treatment at their usualhospitals in the care of whichever physician is involved.
At the same time, it is a priority to collect high-quality
data with respect to HRQL, since this is the primary out-
come of the trial.
The intent of conducting a pragmatic trial, while
still measuring HRQL meticulously, presents a challenge.
Considerable effort has therefore been directed at
designing a trial data management system that can han-
dle distance from participants and maintain close moni-
toring [45]. The system initiates and keeps track of
patient-reported outcomes and identifies a need for trial
personnel input and action. The system also identifies
the site of the information provider and LT4 treatment
duration of new participants, in order to deliver rando-
mization numbers. Meticulous follow-up of missing re-
sponses to the HRQL measurements is incorporated into
the system, to minimize the well-known problem with
missing HRQL data in clinical trials.
The intent to comply with the ICH-GCP guidelines is
also a challenge when conducting a pragmatic trial. In
the CATALYST trial, the experimental intervention is a
dietary supplement rather than a drug. The need to
monitor adverse reactions and events is addressed by a
combination of thorough instruction of the participants
to contact their trial person in case of symptoms
indicative of adverse reactions or events, surveillance of
patients’ responses to prompts through the trial data
management system and integration with national data-
bases regarding hospitalizations.
Trial status
The study protocol is approved by the Regional Scientific
Ethical Committees for Southern Denmark (project ID:
S-20130123) and the first patient visit is scheduled for
April 2014. The schedule is specified in Table 3.
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